Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 5/20 | 0.70 |
| ▸ | EGFR | P00533 | 4/20 | 0.70 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.70 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.70 |
| ▸ | SYK | P43405 | 13/20 | 0.68 |
| ▸ | CDC7 | O00311 | 1/20 | 0.57 |
| ▸ | PLK4 | O00444 | 1/20 | 0.57 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.57 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.57 |
| ▸ | CHUK | O15111 | 1/20 | 0.57 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.57 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.57 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.57 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
| ▸ | PAK4 | O96013 | 1/20 | 0.57 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.57 |
| ▸ | ABL1 | P00519 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3175075 | 0.92 | MAPK8 (0.82) | ITKEGFRMAPK8MAPK9SYK | |
| SCHEMBL3177662 | 0.90 | MAPK8 (0.70) | MAPK8MAPK9SYKAURKB | |
| SCHEMBL14657660 | 0.90 | MAPK8 (0.82) | ITKEGFRMAPK8MAPK9SYK | |
| SCHEMBL3174125 | 0.89 | MAPK8 (0.68) | ITKEGFRMAPK8MAPK9SYK | |
| SCHEMBL14658806 | 0.89 | MAPK8 (0.77) | ITKEGFRMAPK8MAPK9SYK | |
| SCHEMBL3170305 | 0.88 | MAPK8 (0.67) | ITKEGFRMAPK8MAPK9SYK | |
| SCHEMBL3160584 | 0.87 | MAPK8 (0.65) | ITKEGFRMAPK8MAPK9SYK | |
| SCHEMBL21108861 | 0.85 | EGFR (0.80) | ITKEGFRMAPK8MAPK9SYK | |
| SCHEMBL3166777 | 0.85 | MAPK8 (0.70) | ITKMAPK8MAPK9SYKCDC7 | |
| SCHEMBL3174674 | 0.85 | MAPK8 (0.70) | ITKEGFRMAPK8MAPK9SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010025-A1 | Pyrimidine Derivatives | NORVARTIS AG | 2010-01-14 | — | — | US | disclosed |
| US-20100010025-A1 | Pyrimidine Derivatives | NORVARTIS AG | 2010-01-14 | — | — | US | disclosed |
| US-20100010025-A1 | Pyrimidine Derivatives | NORVARTIS AG | 2010-01-14 | — | — | US | disclosed |
| WO-2008009458-A1 | 2, 4 -DI (ARYLAMINIO) -PYRIMIDINE-5-CARBOXAMIDE COMPOUNDS AS JAK KINASES INHIBITORS | NOVARTIS AG (CH) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010025-A1 | Pyrimidine Derivatives | DPYD, TYMP, TYMS | ITK 3383/4885EGFR 4313/4885MAPK8 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.